Maternal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
It is very uncertain whether paracetamol changes maternal adverse events (up to 4 hours and at 6 hours) compared with placebo (very low certainty).
1 finding from 1 review
Neonatal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any breastfeeding at hospital discharge · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any breastfeeding at 6 weeks postpartum · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
NSAID showed no clear difference in maternal adverse events (4 to 8 hours) compared with placebo (low certainty).
1 finding from 1 review
Neonatal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any breastfeeding at hospital discharge · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response to treatment at 8 weeks · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher response to treatment at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to any cause at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects (dropouts) · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to adverse effects at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Remission · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher remission rates at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Change in depressive symptoms · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole showed no clear difference in change in depressive symptoms at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: akathisia (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
Weight gain · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: weight gain (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
All‐cause mortality · pregnant women with fetal growth restriction
1 finding from 1 review
Fetal mortality · pregnant women with fetal growth restriction
1 finding from 1 review
Neonatal mortality · pregnant women with fetal growth restriction
1 finding from 1 review
Mean number of days from treatment initiation to resolution of symptoms or signs (shorter is favored) · epidemic keratoconjunctivitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low